Other languages Glaukos Corporation

Equities

GKOS

US3773221029

Market Closed - Nyse Other stock markets 01:30:02 27/04/2024 am IST			5-day change	1st Jan Change
99.48 ^USD	-0.63%		+3.09%	+25.15%

11/04	Mizuho Securities Adjusts Price Target on Glaukos to $100 From $85, Maintains Neutral Rating	MT
11/04	Glaukos Insider Sold Shares Worth $6,008,359, According to a Recent SEC Filing	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Glaukos Insider Sold Shares Worth $6,008,359, According to a Recent SEC Filing	11/04
Sector Update: Health Care Stocks Rise Wednesday Afternoon	03/04
Glaukos Says iDose TR Assigned Permanent J-Code From US Centers for Medicare and Medicaid Services	03/04
Glaukos Corporation Receives Permanent J-Code for iDose TR (travoprost intracameral implant)	03/04
Glaukos Insider Sold Shares Worth $1,153,557, According to a Recent SEC Filing	09/03
Glaukos Insider Sold Shares Worth $736,000, According to a Recent SEC Filing	01/03
Glaukos Insider Sold Shares Worth $423,487, According to a Recent SEC Filing	27/02
Glaukos Q4 Non-GAAP Loss Widens, Sales Increase	22/02
Glaukos Corporation Reaffirms Financial Guidance for 2024	22/02
Glaukos Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	22/02
Glaukos Insider Sold Shares Worth $436,041, According to a Recent SEC Filing	19/01
Glaukos Preliminary Q4 Net Sales Top Estimates; 2024 Revenue Outlook Reaffirmed; Shares Rise	09/01
Glaukos Corporation Announces Preliminary and Unaudited Net Sales for the Fourth Quarter and Full Year of 2023; Reaffirms Net Sales Guidance for the Year 2024	09/01
Glaukos Insider Sold Shares Worth $7,334,253, According to a Recent SEC Filing	04/01
Sector Update: Health Care Stocks Slipping Late Afternoon	15/12
Sector Update: Health Care	15/12
Glaukos Shares Jump After US FDA Approves New Drug Application for iDose TR	15/12
Sector Update: Health Care Stocks Rise Pre-Bell Thursday	14/12
Glaukos Says FDA Approves New Drug Application for iDose TR	14/12
Glaukos Corporation Re-Affirms Revenue Guidance for the Year 2023 and 2024	14/12

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Glaukos Corporation

Equities

GKOS

US3773221029

Other languages

Filters